Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab

Acta Ophthalmologica

Volumn 90, Issue 1, 2012, Pages

  Carneiro, Ângela M ^a   Costa, Raquel ^a   Falcão, Manuel S ^a   Barthelmes, Daniel ^b   Mendonça, Luis S ^a   Fonseca, Sofia L ^a   Gonçalves, Rita ^a   Gonçalves, Conceição ^a   Falcão Reis, Fernando M ^a   Soares, Raquel ^a  

^a University of Porto   (Portugal)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

AMD; anti VEGF therapy; Avastin ; Lucentis ; VEGF; wet AMD

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LOADING DRUG DOSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETINA MACULA AGE RELATED DEGENERATION; VASCULAR ENDOTHELIAL GROWTH FACTOR BLOOD LEVEL; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84856539058     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2011.02240.x     Document Type: Article

References (48)

1. Ahn JK, &, Moon HJ, (2009): Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration. Am J Ophthalmol 148: 718-724.
2. Alexander SL, Linde-Zwirble WT, Werther W, et al., (2007): Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology 114: 2174-2178. (Pubitemid 350181138)
3. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, &, Singh RJ, (2007a): Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114: 2179-2182. (Pubitemid 350181137)
4. Bakri SJ, Snyder MR, Reid JM, Pulido JS, &, Singh RJ, (2007b): Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114: 855-859. (Pubitemid 46635858)
5. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, &, Noureddin BN, (2008): Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 145: 249-256.
6. Bashshur ZF, Haddad ZA, Schakal AR, Jaafar RF, Saad A, &, Noureddin BN, (2009): Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol 148: 59-65.
7. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, &, Schneider S, (2006): Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432-1444. (Pubitemid 44511558)
8. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, &, Ianchulev T, (2009): Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116: 57-65.
9. Carneiro A, Falcao M, Pirraco A, Milheiro-Oliveira P, Falcao-Reis F, &, Soares R, (2009): Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Exp Eye Res 88: 522-527.
10. Carneiro AM, Barthelmes D, Falcao MS, Mendonca LS, Fonseca SL, Goncalves RM, Faria-Correia F, &, Falcao-Reis FM, (2011): Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica 225: 211-221.
11. Chan WM, Lai TY, Chan KP, Li H, Liu DT, Lam DS, &, Pang CP, (2008): Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina 28: 1308-1313.
12. Christen WG, Glynn RJ, Manson JE, Ajani UA, &, Buring JE, (1996): A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA 276: 1147-1151. (Pubitemid 26329741)
13. Chua B, Flood V, Rochtchina E, Wang JJ, Smith W, &, Mitchell P, (2006): Dietary fatty acids and the 5-year incidence of age-related maculopathy. Arch Ophthalmol 124: 981-986. (Pubitemid 44043098)
14. Congdon N, O'Colmain B, Klaver CC, et al., (2004): Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122: 477-485. (Pubitemid 38456282)
15. Csaky K, &, Do DV, (2009): Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol 148: 647-656.
16. Delcourt C, Diaz JL, Ponton-Sanchez A, &, Papoz L, (1998): Smoking and age-related macular degeneration. The POLA Study. Pathologies Oculaires Liees a l'Age. Arch Ophthalmol 116: 1031-1035. (Pubitemid 29101827)
17. Duan Y, Mo J, Klein R, Scott IU, Lin HM, Caulfield J, Patel M, &, Liao D, (2007): Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans. Ophthalmology 114: 732-737. (Pubitemid 46483682)
18. Ferrara N, &, Kerbel RS, (2005): Angiogenesis as a therapeutic target. Nature 438: 967-974. (Pubitemid 43093963)
19. Ferrara N, Gerber HP, &, LeCouter J, (2003): The biology of VEGF and its receptors. Nat Med 9: 669-676. (Pubitemid 36749215)
20. Ferrara N, Damico L, Shams N, Lowman H, &, Kim R, (2006): Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26: 859-870. (Pubitemid 44547437)
21. Ferris FL III, Fine SL, &, Hyman L, (1984): Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102: 1640-1642. (Pubitemid 15204559)
22. Foran S, Wang JJ, &, Mitchell P, (2003): Causes of visual impairment in two older population cross-sections: the Blue Mountains Eye Study. Ophthalmic Epidemiol 10: 215-225. (Pubitemid 37041277)
23. Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, &, Schmidt-Erfurth U, (2009): Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 116: 2393-2399.
24. Gaudreault J, Fei D, Rusit J, Suboc P, &, Shiu V, (2005): Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46: 726-733. (Pubitemid 40270359)
25. Gaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, Shiu V, &, Damico LA, (2007): Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 27: 1260-1266. (Pubitemid 350211535)
26. Goldberg J, Flowerdew G, Smith E, Brody JA, &, Tso MO, (1988): Factors associated with age-related macular degeneration. An analysis of data from the first National Health and Nutrition Examination Survey. Am J Epidemiol 128: 700-710.
27. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, &, Guyer DR, (2004): Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816. (Pubitemid 40051904)
28. Holz FG, Korobelnik JF, Lanzetta P, et al., (2010): The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 51: 405-412.
29. Khan JC, Thurlby DA, Shahid H, Clayton DG, Yates JR, Bradley M, Moore AT, &, Bird AC, (2006): Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 90: 75-80. (Pubitemid 43029901)
30. Klaver CC, Assink JJ, van Leeuwen R, Wolfs RC, Vingerling JR, Stijnen T, Hofman A, &, de Jong PT, (2001): Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 42: 2237-2241. (Pubitemid 32848852)
31. Klein R, Peto T, Bird A, &, Vannewkirk MR, (2004): The epidemiology of age-related macular degeneration. Am J Ophthalmol 137: 486-495. (Pubitemid 38328641)
32. Klein R, Deng Y, Klein BE, et al., (2007): Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women's Health Initiative Sight Exam ancillary study. Am J Ophthalmol 143: 473-483.
33. Labianca R, Beretta GD, Kildani B, et al., (2010): Colon cancer. Crit Rev Oncol Hematol 74: 106-133.
34. Matsuyama K, Ogata N, Jo N, Shima C, Matsuoka M, &, Matsumura M, (2009): Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab. Jpn J Ophthalmol 53: 243-248.
35. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, &, Nishimura T, (2010): Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 94: 1215-1218.
36. Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Pruente C, Schmidt-Erfurth UM, Tano Y, &, Wolf S, (2010): Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 94: 2-13.
37. Ng EW, &, Adamis AP, (2005): Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 40: 352-368. (Pubitemid 40942262)
38. Ranpura V, Hapani S, Chuang J, &, Wu S, (2010): Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 49: 287-297.
39. Roh MI, Kim HS, Song JH, Lim JB, Koh HJ, &, Kwon OW, (2009): Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with amd after bevacizumab treatment. Retina 29: 523-529.
40. Roh MI, Lim SJ, Ahn JM, Lim JB, &, Kwon OW, (2010): Concentration of cytokines in age-related macular degeneration after consecutive intravitreal bevacizumab injection. Graefes Arch Clin Exp Ophthalmol 248: 635-640.
41. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, &, Kim RY, (2006): Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431. (Pubitemid 44511557)
42. Sawada O, Kawamura H, Kakinoki M, Sawada T, &, Ohji M, (2007): Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 125: 1363-1366. (Pubitemid 47606601)
43. Scappaticci FA, Skillings JR, Holden SN, et al., (2007): Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99: 1232-1239. (Pubitemid 47299901)
44. Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, &, Lelgemann M, (2010): Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr Opin Ophthalmol 21: 218-226.
45. Triano LR, Deshpande H, &, Gettinger SN, (2010): Management of patients with advanced non-small cell lung cancer: current and emerging options. Drugs 70: 167-179.
46. Tsai DC, Charng MJ, Lee FL, Hsu WM, &, Chen SJ, (2006): Different plasma levels of vascular endothelial growth factor and nitric oxide between patients with choroidal and retinal neovascularization. Ophthalmologica 220: 246-251.
47. Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, &, Mauri D, (2010): Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 122: 1-7.
48. Zachary I, Mathur A, Yla-Herttuala S, &, Martin J, (2000): Vascular protection: a novel nonangiogenic cardiovascular role for vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 20: 1512-1520. (Pubitemid 30353882)